{"filing":{"accession_number":"0001104659-26-072324","cik":"0001640266","ticker":"VYGR","company_name":"Voyager Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"tm2617230d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465926072324/tm2617230d1_8k.htm"},"events":[{"id":5595,"run_id":4909,"accession_number":"0001104659-26-072324","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Voyager's stockholders approved the 2026 Annual Meeting matters, including election of three Class II directors (Geraghty, Hyman, Sandrock), an advisory vote on named executive officer compensation, ratification of Ernst \u0026 Young LLP as independent auditor, and an amendment to increase authorized shares from 125 million to 245 million total shares and from 120 million to 240 million common shares.","company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5823,"accession_number":"0001104659-26-072324","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"Voyager's stockholders approved an amendment to increase authorized shares from 125 million to 245 million total shares and from 120 million to 240 million common shares. While this is a routine corporate governance action disclosed under Item 5.03, the doubling of authorized common stock is material to investors as it significantly expands the company's capacity for future equity issuances, dilution, and financing flexibility. This does not fit neatly into the more specific event categories (it is not a dilutive issuance itself, but rather authorization enabling future dilution), so other_material is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:07:56.293520+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5824,"accession_number":"0001104659-26-072324","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 filing discloses the results of Voyager's 2026 Annual Meeting of Stockholders, including election of three Class II directors (Geraghty, Hyman, Sandrock), advisory vote on named executive officer compensation, ratification of Ernst \u0026 Young LLP as independent auditor, and approval of an amendment to increase authorized shares. These are standard shareholder vote results that materially affect corporate governance and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:07:56.293520+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5823,"accession_number":"0001104659-26-072324","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"Voyager's stockholders approved an amendment to increase authorized shares from 125 million to 245 million total shares and from 120 million to 240 million common shares. While this is a routine corporate governance action disclosed under Item 5.03, the doubling of authorized common stock is material to investors as it significantly expands the company's capacity for future equity issuances, dilution, and financing flexibility. This does not fit neatly into the more specific event categories (it is not a dilutive issuance itself, but rather authorization enabling future dilution), so other_material is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:07:56.293520+00:00","company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","filing_date":"2026-06-10"},{"id":5824,"accession_number":"0001104659-26-072324","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 filing discloses the results of Voyager's 2026 Annual Meeting of Stockholders, including election of three Class II directors (Geraghty, Hyman, Sandrock), advisory vote on named executive officer compensation, ratification of Ernst \u0026 Young LLP as independent auditor, and approval of an amendment to increase authorized shares. These are standard shareholder vote results that materially affect corporate governance and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:07:56.293520+00:00","company_name":"Voyager Therapeutics, Inc.","ticker":"VYGR","filing_date":"2026-06-10"}]}